



SP 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tadamitsu KISHIMOTO, et al.

Title: CHRONIC RHEUMATOID ARTHRITIS THERAPY
CONTAINING IL-6 ANTAGONIST AS EFFECTIVE
COMPONENT

Appl. No.: 09/756,125

Filing Date: 01/09/2001

Examiner: G. Ewoldt

Art Unit: 1644

RECEIVED
JUN 18 2003
TECH CENTER 1600/2900

AMENDMENT TRANSMITTAL

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith is an amendment in the above-identified application.

Small Entity status under 37 C.F.R. § 1.9 and § 1.27 has been established by a Small Entity statement previously submitted.

Small Entity statement is enclosed.

The fee required for additional claims is calculated below:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Additional Claims Fee
Total Claims:	8	—	20 = 0	× \$18.00 =	\$0.00
Independents:	2	—	3 = 0	× \$84.00 =	\$0.00
First presentation of any Multiple Dependent Claims:			+ \$280.00 =		\$0.00
			CLAIMS FEE TOTAL:	=	\$0.00

Applicant hereby petitions for an extension of time under 37 C.F.R. § 1.136(a) for the total number of months checked below:

<input type="checkbox"/>	Extension for response filed within the first month:	\$110.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the second month:	\$410.00	\$0.00
<input checked="" type="checkbox"/>	Extension for response filed within the third month:	\$930.00	\$930.00
<input type="checkbox"/>	Extension for response filed within the fourth month:	\$1,450.00	\$0.00
<input type="checkbox"/>	Extension for response filed within the fifth month:	\$1,970.00	\$0.00
	EXTENSION FEE TOTAL:		\$930.00
<input type="checkbox"/>	Statutory Disclaimer Fee under 37 C.F.R. 1.20(d):	\$110.00	\$0.00
	CLAIMS, EXTENSION AND DISCLAIMER FEE TOTAL:		\$930.00
<input type="checkbox"/>	Small Entity Fees Apply (subtract 1/2 of above):		\$0.00
	TOTAL FEE:		\$930.00

Please charge Deposit Account No. 19-0741 in the amount of \$930.00. A duplicate copy of this transmittal is enclosed.

A check in the amount of \$930.00 is enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, applicant hereby petitions for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date June 13, 2003

By Stephen B. Maebius

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5569

Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264



#2410
909a 7/2/3
Atty. Dkt. No. 053466-0296

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tadamitsu KISHIMOTO, et al.

Title: CHRONIC RHEUMATOID ARTHRITIS THERAPY CONTAINING IL-6 ANTAGONIST AS EFFECTIVE COMPONENT

Appl. No.: 09/756,125

Filing Date: 01/09/2001

Examiner: G. Ewoldt

Art Unit: 1644

AMENDMENT AND REPLY UNDER 37 CFR 1.111

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

This is a response to the non-final office action, mailed on December 13, 2002, concerning the above-referenced patent application. By the attached Petition for Extension of Time, Applicants have extended the due date for response until June 13, 2003. Accordingly, this response is timely.

The amendments presented below comply with the revised amendment format permitted in the Notice from the Office of Patent Legal Administration of the U.S. Patent and Trademark Office dated February 10, 2003, and published at 1267 OG 106 on February 25, 2003. Thus, the provisions of 37 CFR 1.121(a), (b), (c) and (d) are waived for amendments to the claims, specification, and drawings of this application.

Amendments to the Claims are reflected in the listing of claims that begins on page 2 of this document.

Amendments to the Specification begin on page 5 of this document.

Remarks/Arguments begin on page 8 of this document.

Please amend the application as follows.